Advanced

Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome

Bogefors, C.; Isaksson, S. LU ; BOBJER, JOHANNES LU ; Kitlinski, M. LU ; Leijonhufvud, I. LU ; Link, Katarina LU and Giwercman, A. LU (2017) In Andrology 5(4). p.711-717
Abstract

More than 95% of testicular cancer are cured but they are at increased long-term risk of cardiovascular disease. The risk of cardiovascular disease and treatment intensity was reported, but it is unknown whether this effect of cancer therapy is direct or indirect, mediated through androgen deficiency. Our aim was, therefore, to evaluate whether testicular cancer patients have increased the prevalence of risk factors of cardiovascular disease and if these risk factors are associated with hypogonadism and/or the cancer treatment given. In 92 testicular cancer patients (mean 9.2 years follow-up) and age-matched controls, blood samples were analysed for lipids, total testosterone, luteinizing hormone (LH), glucose and insulin. An estimate... (More)

More than 95% of testicular cancer are cured but they are at increased long-term risk of cardiovascular disease. The risk of cardiovascular disease and treatment intensity was reported, but it is unknown whether this effect of cancer therapy is direct or indirect, mediated through androgen deficiency. Our aim was, therefore, to evaluate whether testicular cancer patients have increased the prevalence of risk factors of cardiovascular disease and if these risk factors are associated with hypogonadism and/or the cancer treatment given. In 92 testicular cancer patients (mean 9.2 years follow-up) and age-matched controls, blood samples were analysed for lipids, total testosterone, luteinizing hormone (LH), glucose and insulin. An estimate of insulin resistance, HOMAir was calculated. Hypogonadism was defined as total testosterone < 10 nmol/L and/or LH > 10 IU/L and/or androgen replacement. In testicular cancer men with hypogonadism, compared with eugonadal patients, higher insulin (mean difference: 3.10 mIU/L; p = 0.002) and HOMAir (mean difference: 0.792; p = 0.007) were detected. Hypogonadism group presented with increased risk (OR = 4.4; p = 0.01) of metabolic syndrome. Most associations between the treatment given and the metabolic parameters became statistically non-significant after adjustment for hypogonadism. In conclusion, testicular cancer patients with signs of hypogonadism presented with significantly increased risk of metabolic syndrome and investigation of endocrine and metabolic parameters is warranted in these patients.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
hypogonadism, metabolic syndrome, risk, testicular cancer
in
Andrology
volume
5
issue
4
pages
7 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:85024371510
  • wos:000406930900014
ISSN
2047-2919
DOI
10.1111/andr.12354
language
English
LU publication?
yes
id
32872fd3-4590-424b-ae9e-2582e8fd2b24
date added to LUP
2017-08-04 11:16:46
date last changed
2017-09-18 11:40:57
@article{32872fd3-4590-424b-ae9e-2582e8fd2b24,
  abstract     = {<p>More than 95% of testicular cancer are cured but they are at increased long-term risk of cardiovascular disease. The risk of cardiovascular disease and treatment intensity was reported, but it is unknown whether this effect of cancer therapy is direct or indirect, mediated through androgen deficiency. Our aim was, therefore, to evaluate whether testicular cancer patients have increased the prevalence of risk factors of cardiovascular disease and if these risk factors are associated with hypogonadism and/or the cancer treatment given. In 92 testicular cancer patients (mean 9.2 years follow-up) and age-matched controls, blood samples were analysed for lipids, total testosterone, luteinizing hormone (LH), glucose and insulin. An estimate of insulin resistance, HOMAir was calculated. Hypogonadism was defined as total testosterone &lt; 10 nmol/L and/or LH &gt; 10 IU/L and/or androgen replacement. In testicular cancer men with hypogonadism, compared with eugonadal patients, higher insulin (mean difference: 3.10 mIU/L; p = 0.002) and HOMAir (mean difference: 0.792; p = 0.007) were detected. Hypogonadism group presented with increased risk (OR = 4.4; p = 0.01) of metabolic syndrome. Most associations between the treatment given and the metabolic parameters became statistically non-significant after adjustment for hypogonadism. In conclusion, testicular cancer patients with signs of hypogonadism presented with significantly increased risk of metabolic syndrome and investigation of endocrine and metabolic parameters is warranted in these patients.</p>},
  author       = {Bogefors, C. and Isaksson, S. and BOBJER, JOHANNES and Kitlinski, M. and Leijonhufvud, I. and Link, Katarina and Giwercman, A.},
  issn         = {2047-2919},
  keyword      = {hypogonadism,metabolic syndrome,risk,testicular cancer},
  language     = {eng},
  month        = {07},
  number       = {4},
  pages        = {711--717},
  publisher    = {Wiley-Blackwell},
  series       = {Andrology},
  title        = {Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome},
  url          = {http://dx.doi.org/10.1111/andr.12354},
  volume       = {5},
  year         = {2017},
}